Published in Mol Clin Oncol on September 02, 2013
Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure. Lung (2016) 0.81
Preoperative serum levels of mesothelin in patients with colon cancer. Dis Markers (2014) 0.77
A Novel Panel of Serum Biomarkers for MPM Diagnosis. Dis Markers (2017) 0.75
Peritoneal Malignant Mesothelioma with Epithelioid Type, Demonstrating High Serum and Ascitic KL-6 Levels: Immunohistochemical Analyses. Rare Tumors (2015) 0.75
Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics (1988) 70.41
Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart. J Thorac Oncol (2015) 5.83
Mesothelin: a new target for immunotherapy. Clin Cancer Res (2004) 4.30
Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med (2005) 4.11
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg (1999) 3.04
Mesothelin-family proteins and diagnosis of mesothelioma. Lancet (2003) 2.98
Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol (2003) 2.51
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol (2009) 2.26
Malignant pleural mesothelioma. J Clin Oncol (2009) 2.16
The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol (2003) 1.96
Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med (2009) 1.85
Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial. Eur Respir J (2010) 1.74
Diagnostic value of CYFRA 21-1 tumor marker and CEA in pleural effusion due to mesothelioma. Chest (2001) 1.71
Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol (2012) 1.59
Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med (2006) 1.46
Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res (2007) 1.45
MESOMARK: a potential test for malignant pleural mesothelioma. Clin Chem (2007) 1.27
Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg (2008) 1.26
Malignant pleural mesothelioma: an update on biomarkers and treatment. Chest (2009) 1.26
Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin Cancer Res (2007) 1.24
Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma. Chest (2007) 1.20
Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer. Clin Cancer Res (2004) 1.18
Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. J Thorac Oncol (2008) 1.15
Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma. Am J Respir Crit Care Med (2010) 1.14
Prostate-specific antigen and free prostate-specific antigen in the early detection of prostate cancer: do combination tests improve detection? Cancer Epidemiol Biomarkers Prev (2004) 1.02
Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer. J Thorac Oncol (2008) 0.99
Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma--which is best? Lung Cancer (2011) 0.98
Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma. J Thorac Oncol (2011) 0.93
Markers for the non-invasive diagnosis of mesothelioma: a systematic review. Br J Cancer (2011) 0.92
Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels. Clin Chem Lab Med (2010) 0.92
Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure. Cancer Epidemiol Biomarkers Prev (2009) 0.91
Tissue polypeptide antigen (TPA), hyaluronan and CA 125 as serum markers in malignant mesothelioma. Anticancer Res (2003) 0.88
Profiling tumor-associated markers for early detection of malignant mesothelioma: an epidemiologic study. Cancer Epidemiol Biomarkers Prev (2008) 0.87
Soluble markers for diagnosis of malignant pleural mesothelioma. Biomark Med (2011) 0.85
Prognostic value of the serum tumour markers Cyfra 21-1 and tissue polypeptide antigen in malignant mesothelioma. Lung Cancer (1999) 0.84
Soluble mesothelin-related peptides (SMRP) - high stability of a potential tumor marker for mesothelioma. Cancer Biomark (2007) 0.83
Non-invasive diagnosis of pleural malignancies: the role of tumour markers. Lung Cancer (2007) 0.79
Cyfra 21-1 and TPA as markers in malignant mesothelioma. Anticancer Res (1997) 0.79